Lenalidomide maintenance significantly improves progression-free survival (PFS) in patients with chemosensitive relapse of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT) or experienced relapse after transplantation: Results of a multicentre phase II trial

This article has no abstract
Epistemonikos ID: 88193064ca22c8a1287165f850d5ab38dadcfbbc
First added on: Feb 07, 2025